Drug intelligence / Profile preview

LYG-LIV-001

Development stage: Phase 2
Lead developer: LyGenesis
Modality: Cell Therapies
Administration: Intranodal

Overview

LYG-LIV-001 is an allogeneic cell therapy developed by LyGenesis for the treatment of end-stage liver disease (ESLD). The therapy involves the transplantation of donor hepatocytes into a patient's periduodenal lymph nodes using a minimally invasive endoscopic ultrasound procedure. The lymph nodes serve as natural bioreactors, providing the necessary environment for the hepatocytes to engraft, proliferate, and organize into functioning ectopic liver tissue. This approach aims to provide supplemental liver function, potentially addressing the shortage of donor organs by allowing one donated liver to treat multiple patients. The program is currently in Phase 2a clinical development.

Brand names: LYG-LIV0001LYG-LIV-0001LYG-LIV 0001
Other names: allogeneic hepatocyte therapyliver cell therapy

Beyond the preview

Go deeper on LYG-LIV-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LYG-LIV-001.

Explore the full profile